Literature DB >> 31756258

Macrophage-Targeted Isoniazid-Selenium Nanoparticles Promote Antimicrobial Immunity and Synergize Bactericidal Destruction of Tuberculosis Bacilli.

Jiang Pi1,2, Ling Shen1, Enzhuo Yang1, Hongbo Shen3, Dan Huang1, Richard Wang1, Chunmiao Hu1, Hua Jin1, Huaihong Cai4, Jiye Cai4, Gucheng Zeng2, Zheng W Chen1.   

Abstract

Pathogenesis hallmarks for tuberculosis (TB) are the Mycobacterium tuberculosis (Mtb) escape from phagolysosomal destruction and limited drug delivery into infected cells. Several nanomaterials can be entrapped in lysosomes, but the development of functional nanomaterials to promote phagolysosomal Mtb clearance remains a big challenge. Here, we report on the bactericidal effects of selenium nanoparticles (Se NPs) against Mtb and further introduce a novel nanomaterial-assisted anti-TB strategy manipulating Ison@Man-Se NPs for synergistic drug-induced and phagolysosomal destruction of Mtb. Ison@Man-Se NPs preferentially entered macrophages and accumulated in lysosomes releasing Isoniazid. Surprisingly, Ison@Man-Se/Man-Se NPs further promoted the fusion of Mtb into lysosomes for synergistic lysosomal and Isoniazid destruction of Mtb. Concurrently, Ison@Man-Se/Man-Se NPs also induced autophagy sequestration of Mtb, evolving into lysosome-associated autophagosomal Mtb degradation linked to ROS-mitochondrial and PI3K/Akt/mTOR signaling pathways. This novel nanomaterial-assisted anti-TB strategy manipulating antimicrobial immunity and Mtb clearance may potentially serve in more effective therapeutics against TB and drug-resistant TB.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antimicrobial immunity; drug delivery; phagolysosomal destruction; selenium nanoparticles; tuberculosis

Year:  2020        PMID: 31756258     DOI: 10.1002/anie.201912122

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  7 in total

1.  Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.

Authors:  Anirudh Gairola; Aaron Benjamin; Joshua D Weatherston; Jeffrey D Cirillo; Hung-Jen Wu
Journal:  Adv Ther (Weinh)       Date:  2022-03-09

Review 2.  Recent applications and strategies in nanotechnology for lung diseases.

Authors:  Wenhao Zhong; Xinyu Zhang; Yunxin Zeng; Dongjun Lin; Jun Wu
Journal:  Nano Res       Date:  2021-01-08       Impact factor: 8.897

3.  GE11 Peptide Conjugated Liposomes for EGFR-Targeted and Chemophotothermal Combined Anticancer Therapy.

Authors:  Xueqin Huang; Lingzhi Chen; Yuping Zhang; Suyan Zhou; Huai-Hong Cai; Ting Li; Hua Jin; Jiye Cai; Haibo Zhou; Jiang Pi
Journal:  Bioinorg Chem Appl       Date:  2021-03-31       Impact factor: 7.778

Review 4.  Regulatory Mechanisms of Autophagy-Targeted Antimicrobial Therapeutics Against Mycobacterial Infection.

Authors:  Prashanta Silwal; Seungwha Paik; Jin Kyung Kim; Tamotsu Yoshimori; Eun-Kyeong Jo
Journal:  Front Cell Infect Microbiol       Date:  2021-03-22       Impact factor: 5.293

5.  Nanocages engineered from Bacillus Calmette-Guerin facilitate protective Vγ2Vδ2 T cell immunity against Mycobacterium tuberculosis infection.

Authors:  Jiang Pi; Zhiyi Zhang; Enzhuo Yang; Lingming Chen; Lingchan Zeng; Yiwei Chen; Richard Wang; Dan Huang; Shuhao Fan; Wensen Lin; Hongbo Shen; Jun-Fa Xu; Gucheng Zeng; Ling Shen
Journal:  J Nanobiotechnology       Date:  2022-01-15       Impact factor: 10.435

Review 6.  Immunomodulatory roles of selenium nanoparticles: Novel arts for potential immunotherapy strategy development.

Authors:  Gengshi Chen; Fen Yang; Shuhao Fan; Hua Jin; Kangsheng Liao; Xuemeng Li; Gan-Bin Liu; Jing Liang; Junai Zhang; Jun-Fa Xu; Jiang Pi
Journal:  Front Immunol       Date:  2022-07-26       Impact factor: 8.786

Review 7.  Diagnosis and treatment of tuberculosis in adults with HIV.

Authors:  Qiaoli Yang; Jinjin Han; Jingjing Shen; Xinsen Peng; Lurong Zhou; Xuejing Yin
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.